Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TC BioPharm Holdings PLC (TCBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/21/2025: TCBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.86% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.36M USD | Price to earnings Ratio - | 1Y Target Price 140 |
Price to earnings Ratio - | 1Y Target Price 140 | ||
Volume (30-day avg) 686574 | Beta 0.25 | 52 Weeks Range 0.50 - 523.20 | Updated Date 03/23/2025 |
52 Weeks Range 0.50 - 523.20 | Updated Date 03/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -192.95 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -108.92% | Return on Equity (TTM) -1217.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1100637 | Price to Sales(TTM) 0.51 |
Enterprise Value 1100637 | Price to Sales(TTM) 0.51 | ||
Enterprise Value to Revenue 1.83 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 572021 | Shares Floating 98445670 |
Shares Outstanding 572021 | Shares Floating 98445670 | ||
Percent Insiders 0.01 | Percent Institutions 1.76 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TC BioPharm Holdings PLC: A Comprehensive Overview
Company Profile:
History and Background:
TC BioPharm (TCBPF) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Beijing, China. The company focuses on developing novel therapies for autoimmune and inflammatory diseases with high unmet medical needs.
Core Business Areas:
TC BioPharm's primary activity revolves around the development and commercialization of antibody-based therapies. Their pipeline includes various monoclonal antibodies targeting different inflammatory pathways.
Leadership Team and Corporate Structure:
The leadership team consists of experienced professionals with expertise in drug development, clinical research, and business development. The company operates through a decentralized structure with subsidiaries in China and the United States.
Top Products and Market Share:
TC BioPharm is yet to have commercially available products as they are primarily in the clinical development stage. Their lead product, TC-B1106, is a humanized anti-CD38 monoclonal antibody for the potential treatment of multiple autoimmune diseases. The company is also developing several other drug candidates for various inflammatory conditions.
Total Addressable Market:
The global market for autoimmune and inflammatory diseases is vast and projected to reach $184.3 billion by 2027.
Financial Performance:
TC BioPharm is currently in the clinical development stage and has not yet generated any revenue. The company's financial performance is characterized by ongoing research and development expenses.
Dividends and Shareholder Returns:
As a pre-revenue company, TC BioPharm does not currently pay dividends.
Growth Trajectory:
TC BioPharm's growth trajectory is highly dependent on the success of its clinical trials and potential regulatory approvals. The company has experienced significant share price volatility due to its early-stage development status.
Market Dynamics:
The autoimmune and inflammatory disease market is a highly competitive landscape with a diverse range of established players and emerging biotech companies. TC BioPharm's success will hinge on its ability to demonstrate the efficacy and safety of its therapies, differentiate itself from competitors, and secure market access.
Competitors:
Key competitors in the autoimmune and inflammatory disease market include:
- AbbVie (ABBV)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Pfizer (PFE)
- Johnson & Johnson (JNJ)
Potential Challenges and Opportunities:
Challenges:
- Clinical development risks: The success of TC BioPharm's pipeline depends on the outcome of ongoing clinical trials.
- Regulatory hurdles: Obtaining regulatory approvals for new therapies can be a lengthy and expensive process.
- Competition: The company faces intense competition from established players in the market.
Opportunities:
- Large addressable market: The market for autoimmune and inflammatory diseases offers significant growth potential.
- Unmet medical needs: TC BioPharm's therapies target diseases with high unmet medical needs, creating potential for substantial market penetration.
- Strategic partnerships: Collaborations with larger pharmaceutical companies could accelerate development and commercialization efforts.
Recent Acquisitions:
TC BioPharm has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Rating: 5/10
This rating reflects the company's early-stage development status, lack of revenue, and the inherent risks associated with clinical-stage companies. However, the significant market opportunity and potential for breakthrough therapies offer some upside potential.
Sources and Disclaimers:
- TC BioPharm Holdings PLC website (https://www.tcbiopharm.com/)
- SEC filings: https://www.sec.gov/edgar/search/#/
- Market research reports: https://www.grandviewresearch.com/industry-analysis/autoimmune-and-inflammatory-diseases-market
Disclaimer: This information is provided for educational purposes only and should not be considered investment advice. It is essential to conduct your research and consult with a qualified financial advisor before making any investment decisions.
Additional Notes:
- This overview is based on publicly available information as of November 23, 2023.
- Due to the rapid pace of change in the market, some information may become outdated.
- It is recommended to continuously monitor the company's progress and market conditions for the most up-to-date assessment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TC BioPharm Holdings PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-02-11 | CEO & Director Mr. Bryan Leland Kobel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://tcbiopharm.com |
Full time employees 41 | Website https://tcbiopharm.com | ||
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.